GGrantIndex
← Leaderboards

Robin K Ohls

University Of New Mexico

Google Scholar ↗PubMed ↗ORCID ↗
$8,058,323
Attributed
$13,289,432
Total exposure
29
Grants
21
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.6M · FY2005–25
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$13,289,432 · 29

By mechanism

R01$8,778,976 · 2
UG1$1,873,380 · 1
U01$1,820,030 · 1
M01$817,046 · 25

Top collaborators

Most similar at University Of New Mexico

Same institution · by research overlap

Others in their field

Top investigators on “Funding”

Research focus

FundingPremature InfantRandomizedInfantResearch PersonnelUnited States National Institutes Of HealthFollow-UpLifeChildResourcesSourceUniversitiesResponseDoseInstitutionComputer Retrieval Of Information On Scientific Projects DatabaseGrantNeonatalHematocrit ProcedureGestational AgeVery Low Birth Weight InfantErythropoietinEvaluationClinical Research

Grant awards (48)

The Darbepoetin Kindergarten Development Study$2,108,079
R01 · FY2025 · HL
NICHD Cooperative Multicenter Neonatal Research Network - Utah Center$339,184
UG1 · FY2025 · HD · contact PI
The Darbepoetin Kindergarten Development Study$2,175,984
R01 · FY2024 · HL
NICHD Cooperative Multicenter Neonatal Research Network - Utah Center$345,165
UG1 · FY2024 · HD · contact PI
The Darbepoetin Kindergarten Development Study$2,254,823
R01 · FY2023 · HL
NICHD Cooperative Multicenter Neonatal Research Network - Utah Center$344,885
UG1 · FY2023 · HD · contact PI
NICHD Cooperative Multicenter Neonatal Research Network - Utah Center$281,382
UG1 · FY2022 · HD · contact PI
Darbepoetin Trial to Improve Red Cell Mass and Neurodevelopment in Preterms-CCC$316,106
U01 · FY2021 · HL · contact PI
NICHD Cooperative Multicenter Neonatal Research Network - Utah Center$281,382
UG1 · FY2021 · HD · contact PI
Darbepoetin Trial to Improve Red Cell Mass and Neurodevelopment in Preterms-CCC$350,763
U01 · FY2020 · HL · contact PI
NICHD Cooperative Multicenter Neonatal Research Network - Utah Center$281,382
UG1 · FY2020 · HD · contact PI
Darbepoetin Trial to Improve Red Cell Mass and Neurodevelopment in Preterms-CCC$359,962
U01 · FY2019 · HL · contact PI
Darbepoetin Trial to Improve Red Cell Mass and Neurodevelopment in Preterms-CCC$436,233
U01 · FY2018 · HL · contact PI
Darbepoetin Trial to Improve Red Cell Mass and Neurodevelopment in Preterms-CCC$356,966
U01 · FY2017 · HL · contact PI
Brain imaging and developmental follow-up of infants treated with erythropoietin$434,951
R01 · FY2014 · HD · contact PI
Brain imaging and developmental follow-up of infants treated with erythropoietin$418,594
R01 · FY2013 · HD · contact PI
Brain imaging and developmental follow-up of infants treated with erythropoietin$415,102
R01 · FY2012 · HD · contact PI
Brain imaging and developmental follow-up of infants treated with erythropoietin$471,528
R01 · FY2011 · HD · contact PI
Brain imaging and developmental follow-up of infants treated with erythropoietin$499,915
R01 · FY2010 · HD · contact PI
A RANDOMIZED, MASKED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND$73,624
M01 · FY2010 · RR · contact PI
BIOMARKER PROFILES AS PREDICATORS OF NEONATAL SEPSIS AND RECOVERY$25,488
M01 · FY2010 · RR · contact PI
A RANDOMIZED, MASKED STUDY OF WEEKLY ERYTHOPOIETIN DOSING$5,977
M01 · FY2010 · RR · contact PI
A RANDOMIZED, MASKED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND$105,700
M01 · FY2009 · RR · contact PI
BIOMARKER PROFILES AS PREDICATORS OF NEONATAL SEPSIS AND RECOVERY$84,333
M01 · FY2009 · RR · contact PI
A RANDOMIZED, MASKED STUDY OF WEEKLY ERYTHOPOIETIN DOSING$52,163
M01 · FY2009 · RR · contact PI
A RANDOMIZED DOSE-RESPONSE STUDY TO ASSESS THE SAFETY AND PRELIMINARY EFFICACY$24,945
M01 · FY2009 · RR · contact PI
RANDOMIZED CLINICAL TRIAL OF INHALED PGE, IN NEONATAL HYPOXEMIC RESPIRATORY$2,752
M01 · FY2009 · RR · contact PI
A RANDOMIZED, MASKED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND$56,912
M01 · FY2008 · RR · contact PI
A RANDOMIZED, MASKED STUDY OF WEEKLY ERYTHOPOIETIN DOSING$47,438
M01 · FY2008 · RR · contact PI
BIOMARKER PROFILES AS PREDICATORS OF NEONATAL SEPSIS AND RECOVERY$18,680
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: A RANDOMIZED DOSE-RESPONSE STUDY TO ASSESS THE SAFETY AND PRELIM$14,464
M01 · FY2008 · RR · contact PI
A RANDOMIZED, MASKED STUDY OF WEEKLY ERYTHOPOIETIN DOSING$29,092
M01 · FY2007 · RR · contact PI
A RANDOMIZED, MASKED, PLACEBO-CONTROLLED STUDY$28,601
M01 · FY2007 · RR · contact PI
A RANDOMIZED DOSE-RESPONSE STUDY TO ASSESS THE SAFETY AND PRELIMINARY EFFICACY$4,510
M01 · FY2007 · RR · contact PI
A RANDOMIZED DOSE-RESPONSE STUDY TO ASSESS THE SAFETY AND PRELIMINARY EFFICACY$59,913
M01 · FY2006 · RR · contact PI
PLACEBO-CONTROLLED STUDY EVALUATING RECOMBINANT ERYTHROPOIETIN$6,959
M01 · FY2006 · RR · contact PI
INFLAMMATORY MEDIATORS AS PREDICTORS OF NEONATAL SEPSIS & RECOVERY$4,662
M01 · FY2006 · RR · contact PI
A RANDOMIZED DOSE-RESPONSE STUDY TO ASSESS THE SAFETY AND PRELIMINARY EFFICACY$40,333
M01 · FY2005 · RR
INFLAMMATORY MEDIATORS AS PREDICTORS OF NEONATAL SEPSIS &RECOVERY$27,139
M01 · FY2005 · RR
PLACEBO-CONTROLLED STUDY EVALUATING RECOMBINANT ERYTHROPOIETIN$24,078
M01 · FY2005 · RR
THE ABILITY OF HEALTHCARE PROVIDERS TO PREDICT ANTICIPATORY GRIEF IN THE NICU$11,662
M01 · FY2005 · RR
ASSESS THE SAFETY AND PRELIMINARY EFFICACY OF MULTIPLE DOSES OF INH-A21$1,169
M01 · FY2005 · RR
EVALUATION OF NOVEL ERYTHROPOIESIS STIMULATING PROTEIN$251
M01 · FY2005 · RR
Safety and Preliminary Efficacy of INH-A21$44,078
M01 · FY2004 · RR
Controlled Study Evaluating Recombinant Erythropoietin$15,670
M01 · FY2004 · RR
Inflammatory Mediators as Predictors of Neonatal Sepsis &Recovery$4,358
M01 · FY2004 · RR
Evaluation of Novel Erythropoiesis Stimulating Protein$2,011
M01 · FY2004 · RR
hrThrombopoietin (TPO) on Growth of Megakaryocyte$84
M01 · FY2004 · RR